Tentt

Eli Lilly to Acquire Ventyx Biosciences for $1.2B

Announced
HealthcareMerger

Deal Overview

Eli Lilly and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in an all-cash transaction valued at approximately $1.2 billion. The acquisition is intended to develop oral therapies for inflammatory-mediated diseases.

Ventyx’s pipeline includes NLRP3 inhibitors aimed at cardiometabolic, neurodegenerative, and autoimmune conditions. The transaction is expected to close in the first half of 2026, subject to regulatory approvals and stockholder consent.

Key Details

Transaction
Eli Lilly acquires Ventyx Biosciences
Deal Size
Over $100M
Reported Value
$1.2 billion

Filed under

Source

Read full article on news.google.com

via GN - definitive agreement acquisition · January 8, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →